A deafened adult cannot recover the ability to hear, because the sensory hearing cells of the inner ear don’t regenerate after damage.
Poseida lines up another allogeneic CAR-T partner, allying with Astellas on solid tumors
Astellas will buy about 8.8% of Poseida Therapeutics for $25 million, and match that with a one-time payment for right of first refusal to license
August 8, 2023